Precigen Inc (PGEN) - Total Liabilities
Based on the latest financial reports, Precigen Inc (PGEN) has total liabilities worth $135.71 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Precigen Inc equity growth rate to track the company's year-over-year net asset growth rate.
Precigen Inc - Total Liabilities Trend (2011–2025)
This chart illustrates how Precigen Inc's total liabilities have evolved over time, based on quarterly financial data. See cash generation quality of Precigen Inc to measure how efficiently the company converts operating cash flow to free cash.
Precigen Inc Competitors by Total Liabilities
The table below lists competitors of Precigen Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
FirstSun Capital Bancorp Common Stock
NASDAQ:FSUN
|
USA | $7.39 Billion |
|
Macmahon Holdings Ltd
AU:MAH
|
Australia | AU$992.39 Million |
|
Zhongmin Energy Co Ltd
SHG:600163
|
China | CN¥4.65 Billion |
|
YGSOFT Inc
SHE:002063
|
China | CN¥654.07 Million |
|
Shanghai Liangxin Electrical Co Ltd
SHE:002706
|
China | CN¥1.91 Billion |
|
Jiangsu Changfa Refrigeration Co Ltd
SHE:002413
|
China | CN¥1.66 Billion |
|
Great Wall Enterprise Co Ltd
TW:1210
|
Taiwan | NT$40.68 Billion |
|
ALPEK S.A.B. de C.V
MX:ALPEKA
|
Mexico | MX$71.16 Billion |
Liability Composition Analysis (2011–2025)
This chart breaks down Precigen Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see PGEN stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.09 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 6.49 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.87 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Precigen Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Precigen Inc (2011–2025)
The table below shows the annual total liabilities of Precigen Inc from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $135.71 Million | +27.13% |
| 2024-12-31 | $106.75 Million | +228.02% |
| 2023-12-31 | $32.55 Million | -63.73% |
| 2022-12-31 | $89.72 Million | -64.47% |
| 2021-12-31 | $252.51 Million | +2.06% |
| 2020-12-31 | $247.41 Million | -35.58% |
| 2019-12-31 | $384.05 Million | +13.81% |
| 2018-12-31 | $337.45 Million | +12.37% |
| 2017-12-31 | $300.31 Million | -20.93% |
| 2016-12-31 | $379.82 Million | +37.04% |
| 2015-12-31 | $277.16 Million | +65.98% |
| 2014-12-31 | $166.98 Million | +89.48% |
| 2013-12-31 | $88.13 Million | -81.38% |
| 2012-12-31 | $473.20 Million | +40.80% |
| 2011-12-31 | $336.09 Million | -- |
About Precigen Inc
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors… Read more